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Results There was no significant difference in age, PSA, 
prostate volume, time-to-biopsy, and number of cores 
obtained between the groups. A greater proportion of target 
cores were positive for cancer (158/228; 69.3 %) compared 
to background (344/1881; 18.38 %). The median target vol-
ume was 0.54 cm3 for Group 1 (range 0.09–2.79 cm3) and 
1.65 cm3 for Group 2 (0.3–9.07 cm3), p < 0.001. The targets 
in Group 1 had statistically lower diameters for short and 
long axes, even after correction for gland size. The highest 
area under the receiver operating characteristic curve was 
demonstrated when a lesion cutoff value of 1.0 cm in short 
axis was applied, resulting in a sensitivity of 83.3 % and a 
specificity of 82.9 %.
Conclusions When a combined systematic and targeted 
transperineal prostate biopsy is performed, there is limited 
Abstract 
Purpose To compare histological outcomes in patients 
undergoing MRI–transrectal ultrasound fusion transper-
ineal (MTTP) prostate biopsy and determine the incremen-
tal benefit of targeted cores.
Methods Seventy-six consecutive patients with 89 MRI-
identified targets underwent MTTP biopsy. Separate 
targeted biopsies and background cores were obtained 
according to a standardized protocol. Target biopsies were 
considered of added diagnostic value if these cores showed 
a higher Gleason grade than non-targeted cores taken from 
the same sector (Group 1, n = 41). Conversely, where 
background cores demonstrated an equal or higher Gleason 
grade, target cores were considered to be non-beneficial 
(Group 2, n = 48).
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benefit in acquiring additional cores from larger-volume 
targets with a short axis diameter >1.0 cm.
Keywords Image-guided biopsy · Magnetic resonance 
imaging · Ultrasound · Transperineal · Prostate cancer
Introduction
Prostate cancer is unique among solid organ tumors in 
being predominantly diagnosed by an indirect, non-tar-
geted biopsy method. However, transrectal ultrasound-
guided (TRUS) biopsy is constrained by inherent sampling 
error and suboptimal detection efficiency, failing to detect 
up to 30 % of cancers [1, 2] and underestimating tumor 
aggressiveness in around one-third of cases [3]. There is 
now a substantial body of evidence validating multi-para-
metric magnetic resonance imaging (mp-MRI) as a means 
of detecting prostate tumors [4, 5]. Furthermore, MRI-
guided targeting has been shown to significantly improve 
risk stratification by reducing sampling error [6]. As a 
result, some authors now recommend mp-MRI as a means 
of directing either initial or repeat biopsies of the prostate, 
following a previous negative TRUS [7, 8]. Increasingly, a 
transperineal (TP) approach to biopsy is being utilized as it 
offers several advantages over the transrectal route, includ-
ing reduced rates of sepsis and an increased ability to sam-
ple tumors located in the anterior and apical regions of the 
prostate [9, 10].
MRI-targeted prostate biopsies have significantly higher 
rates of detection for clinically significant cancer, being 
associated with a higher percentage of positive cores and 
longer maximum cancer core length (MCCL) compared 
to systematic biopsies [11–13]. Targeted cores have also 
been shown to reduce the detection of incidental, clini-
cally insignificant tumors [14, 15]. However, mp-MRI is 
known to have a false-negative rate, which can depend on 
the experience of the reporting radiologist and the thresh-
old used to define a positive MRI [16]. Therefore, the back-
ground gland is often sampled in addition to targeted cores 
to ensure that, in the case of negative targets, MRI occult 
tumor is not present elsewhere. Recent recommenda-
tions for MRI-guided transperineal biopsy from the Gins-
burg study group suggest that additional cores should be 
acquired from the same sector as the target cores as well 
as defined standard background sectors [17]. However, the 
acquisition of additional target cores to achieve the correct 
diagnosis needs to be balanced against limiting the over-
all number of biopsies taken, as well as the cost and the 
time required to undertake the MRI fusion biopsies. Tak-
ing more cores may bring an increased risk of morbidity 
[18]. Previous work suggests saturation TP biopsies per-
formed prior to radical prostatectomy can make surgery 
more challenging and lead to increased complication rates 
[19]. Additionally, the need for a general anesthetic with a 
transperineal approach has an effect on both patients and 
provider capacities and is a barrier to its widespread use. 
Importantly, which MRI targets are more likely to benefit 
from a targeted biopsy approach and which may be easily 
biopsied without image fusion is still unknown.
The current requirement is therefore to acquire the 
minimum number of biopsy cores that will simultaneously 
allow the detection of the index lesion or lesions, while 
minimizing the risk of false-negative results. The aim of 
this study was to compare the characteristics of targets in 
patients undergoing standardized MRI-guided prostate 
biopsy and to identify when targeted cores are most benefi-
cial in terms of cancer yield and grade stratification. Ulti-
mately, the aim was to determine whether there are cases 
where there is no added benefit in targeting the biopsy.
Methods
Patient cohort
This retrospective review of outcomes was granted ethical 
approval by the local review committee, with the need for 
written informed consent waived. Seventy-six consecutive 
patients undergoing targeted MRI–TRUS fusion transper-
ineal (MTTP) biopsy over an 18-month period from April 
2013 to September 2014 were identified, meeting the inclu-
sion criteria of a high-probability target lesion identified by 
the radiologist (see below) and tumor subsequently con-
firmed by the pathologist. Data were recorded according to 
the standards of reporting for MRI-targeted biopsy studies 
(START) of the prostate [20].
Magnetic resonance imaging
MRI was performed on a 3.0-T DiscoveryMR750 (General 
Electric Healthcare, Waukesha, USA) with an 8-channel 
phased-array coil. The imaging protocol included axial T1-
weighted spin echo images of the pelvis and high-resolu-
tion T2-weighted (T2W) fast-recovery fast spin-echo images 
centered on the prostate in the axial (slice thickness 3 mm), 
coronal, and sagittal planes. Axial diffusion-weighted 
imaging (DWI) was performed using a customized dual-
spin echo-planar imaging pulse sequence (b values 50, 750, 
1000, 1400 s/mm2). Apparent diffusion coefficient (ADC) 
maps were reconstructed using software programmed with 
MATLAB (MathWorks, Natick, MA).
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Image analysis
MRI images were interpreted by two attending uroradi-
ologists with between 3- and 5-year experience in reading 
prostate MRIs. T2W and DWI images were evaluated using 
the prostate imaging-reporting and data system (PI-RADS) 
criteria [21]. The scoring system of MRI targets was based 
on a Likert scale: 1—significant cancer highly unlikely, 
2—significant cancer unlikely, 3—intermediate probabil-
ity, 4—significant cancer likely, and 5—significant cancer 
highly likely. Positive MRIs were defined as having high-
probability targets with a score of 4 or 5. In cases of a posi-
tive MRI, additional targeted biopsy cores were obtained. 
Targets were prospectively drawn as a region-of-interest 
(ROI) contour and saved to the picture archiving and com-
munication system (PACS).
MRI–TRUS fusion transperineal (MTTP) biopsy
Transperineal biopsies were performed using the Biopsee® 
MRI–TRUS fusion biopsy platform (Medcom, Darmstadt, 
Germany). Briefly, a transrectal ultrasound probe is inserted 
and mounted on a brachytherapy gantry with a template 
grid for transperineal needle placement in the prostate. 
MR images are co-registered to ultrasound images allow-
ing prospectively determined targets to be outlined, along 
with whole-gland outlines. MTTP biopsies were performed 
according to the standards proposed by the Ginsburg study 
group, with 24–36 core biopsies obtained from standard-
ized sectors, depending on prostate size, and additional 
biopsy cores taken from MRI-defined target(s) [17]. Three 
types of biopsy core were therefore obtained: (1) back-
ground sector biopsy cores (BSB; systematic cores taken 
from Ginsburg-defined sectors), (2) target biopsy cores 
(TB; cores taken from the target delineated on MRI), and 
(3) target sector biopsy cores (TSB; cores taken from a sec-
tor which contains a target). Biopsies were performed by 
attending urologists with the knowledge of the MRI result 
and using the pre-defined ROIs to guide biopsy. Targeted 
cores were obtained before the sector biopsies, with all tar-
get and sector cores placed into separate histology pots.
Data collection
The following data were collected: indications for biopsy; 
patient demographics; biopsy core information; histopa-
thology outcomes; prostate volume; target volume; axial 
prostate; and axial target dimensions. Information relating 
to target volume and gland volume is prospectively stored 
on the BiopSee® MRI–TRUS fusion device, and these data 
were retrospectively collected for all cases. In addition to 
volume, the axial dimensions of the target and prostate 
were also recorded as they represent simple, reproducible 
metrics which can be acquired as part of routine clini-
cal reporting to determine the suitability for biopsy. Axial 
dimensions for prostate were obtained from the axial T2-
weighted MRI by measuring the largest transverse and 
antero-posterior diameters. The targets were also measured 
on the axial T2 images, by first identifying the maximum 
diameter which was determined to be the “long axis” of the 
target; the “short axis” was determined as the measurement 
perpendicular to this long axis diameter in the same axial 
plane.
Comparing the number of positive tumor cores acquired 
from targeted biopsies (TB) to the number of positive back-
ground cores taken from the same sector (TSB) provides a 
measure of the added benefit of undertaking these targeted 
biopsies. Targets were therefore retrospectively split into 
two groups for analysis: Group 1, where TB cores con-
tained higher Gleason grade tumor than TSB cores; Group 
2, where TSB cores contained an equal or higher Gleason 
grade than TB cores (Fig. 1).
Statistical analysis
The distributions were assessed to establish whether they 
met normality assumptions. Statistical inferences were per-
formed using the nonparametric Mann–Whitney U test to 
investigate the differences between groups in demographic 
and background information. Group differences in the plan-
imetry-derived target volume metrics were also compared 
using this test.  Fisher’s exact test was used to compare cat-
egorical Gleason data. Statistical significance was defined as 
a p value <0.05. Integrated areas under the receiver operating 
characteristic (ROC) curve were computed as determined 
by the relationship between specificity and sensitivity. The 
optimal cutoff for stratifying the groups was determined 
as the shortest Euclidean distance between 100 % specific-
ity and sensitivity and the ROC curve. Pearson’s correlation 
was used to compare both total cores taken and cancer core 
involvement to tumor volume. All the statistical analyses 
were performed using the R programming language (version 
3.1.1, The R foundation for statistical computing, Vienna, 
Austria) and the pROC package (version 1.7.3) [22].
Results
Seventy-six patients with a median age of 68 years (range 
53–76) and a median PSA of 8.9 ng/ml (range 0.8–53.2) 
met the inclusion criteria. A total of 89 high-probability 
MRI targets were identified (2 targets in 11 patients, 3 tar-
gets in 1 patient). The indication for biopsy and informa-
tion on prior biopsy are listed in Table 1.
Of 89 targets, 41 demonstrated higher Gleason grade in 
the target biopsy cores (Group 1), and 48/89 demonstrated 
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equal or higher Gleason grade in the target sector biopsy 
cores (Group 2). There was no statistical difference 
between the two groups in terms of patient age, PSA, 
MRI score, prostate volume, time from MRI to biopsy, 
and total target or background biopsy cores obtained 
(Table 2). In 32/41 cases within Group 1, TSB were 
benign in comparison with the TB cores which showed 
tumor; in six cases, TSB cores showed Gleason 3 + 3 dis-
ease and TB cores showed ≥3 + 4 disease. In 30/48 cases 
in Group 2, the Gleason grade was equal in the TB and 
TSB cores; six cases had benign TB cores with positive 
corresponding TSB cores. Overall, a greater proportion 
of TB cores were positive for cancer (158/228; 69.3 %) 
compared to combined TSB and BSB cores (344/1881; 
18.4 %) (Table 3).
The median overall target volume was 1.09 cm3 (mean 
1.53, range 0.09–9.07 cm3). The median target volume for 
Group 1 was significantly lower at 0.54 cm3 [95 % confi-
dence interval (CI) 0.41–1.04; range 0.09–2.79 cm3] com-
pared to Group 2 with a median volume 1.65 cm3 (95 % 
CI 1.08–2.78, range 0.3–9.07 cm3), p < 0.001 (Fig. 2). 
This relationship held regardless of overall gland size, with 
results being similar when target volumes were expressed 
as a percentage of overall gland volume. Targets in Group 
1 had a statistically significant lower longest and shortest 
axis diameter compared to Group 2, and this relationship 
was unchanged when diameter was expressed as a percent-
age of axial gland dimensions (Table 4).
The area under the curve (AUC) of the receiver operat-
ing characteristic (ROC) curves ranged from 0.738 to 0.927 
for all the variables assessed (Table 4). The highest AUC 
was demonstrated for the shortest axis measurement of tar-
gets, which demonstrated a sensitivity of 83.3 and a speci-
ficity of 82.9, at a cutoff value of 1.0 cm (Fig. 3).
There was no observable correlation between the num-
ber of target cores and the target volume (r = −0.055, 
p = 0.612). However, there was a positive correlation 
between the number of target sector cores acquired and the 
target volume (r = 0.322, p = 0.002); this is expected as 
the larger target will overlap with more sectors. For the 83 
case with positive target cores, the average maximum can-
cer core length (MCCL) was 4.6 mm (range 0.5–15 mm) 
with a mean percentage core involvement of 34.1 % 
(range 1–95 %). There was a positive Pearson’s correla-
tion between both MCCL and tumor volume (r = 0.693) 
and percentage core involvement and tumor volume 
(r = 0.554).
Fig. 1  Target sector cores with higher Gleason grade than tar-
get cores. a Axial T2-weighted image shows a large lesion (volume 
6.09 cm3) in the lateral and anterior left mid-peripheral zone, and b 
axial diffusion-weighted image shows marked restricted diffusion. c 
Peri-procedure axial US with target outline and biopsy plan. Both tar-
get cores demonstrated Gleason 4 + 3 disease, and background cores 
from the target sector demonstrated higher grade, Gleason 4 + 5 dis-
ease
Table 1  Biopsy demographics
TRUS transrectal ultrasound, PSA prostate-specific antigen, HGPIN 
high-grade prostatic intraepithelial neoplasia, ASAP atypical small 
acinar proliferation
Indication for biopsy (N = 76)
 Raised PSA 18
 Previous TRUS negative, rising PSA 15
 Previous TRUS with suspicious changes 16
 Active surveillance 26
 BRCA-2 mutation 1










Gleason grade of previous positive biopsies (N = 26)
 3 + 3 18
 3 + 4 5
 4 + 3 3
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Discussion
MRI is now established as the imaging modality of choice 
in the workup of organ-confined prostate cancer. MRI-
guided targeted prostate biopsy is a logical next step to 
improve the accuracy and yield of diagnosis; however, this 
typically incurs additional costs in terms of the fusion soft-
ware required and time taken to plan and perform proce-
dures. Furthermore, although transperineal biopsies under 
local anesthetic have been described, a standardized vali-
dated technique is yet to be agreed, and reducing the num-
ber of cores may be the key to establishing this in select 
patients. This study has investigated the added value of 
MRI-targeted biopsies over non-targeted background cores 
and has demonstrated that there may be cases when there is 
no added benefit in undergoing a targeted biopsy in addi-
tion to the background template biopsies; in particular, it 
has addressed for the first time whether the size of the tar-
get may play a role in the sensitivity of MRI targeting.
This work has shown that there is a relationship between 
the size of a defined target and the additional value of tar-
geted transperineal prostate biopsy for detecting the highest 
Table 2  Patient demographics
Range (median) listed, unless stated. Group 1: target biopsy cores show higher Gleason grade; Group 2: 
target sector biopsy cores show equal or higher Gleason grade
Overall Group 1 Group 2 p value
Age (years) 53–76 (68) 53–75 (67) 53–76 (69) 0.368
PSA (ng/ml) 0.8–53.2 (8.9) 0.8–32 (8.9) 1.2–53.2 (9.9) 0.383
MRI score 4: N 33 18 15 0.273
MRI score 5: N 56 23 33
Gland volume (cm3) 13.9–292.6 (43.2) 13.9–175.7 (48.8) 16.86–292.6 (40.4) 0.089
Time from MRI to biopsy (days) 12–90 (48.5) 12–90 (44) 17–85 (50.5) 0.285
Target cores: total (range; median) 228 (1–7; 2) 106 (2–6; 2) 122 (1–7; 2) 0.760
Total cores: total (range; median) 2109 (19–34; 28) 1189 (19–32; 28) 1297 (20–34; 28) 0.118
Table 3  Pathology outcomes
Group 1: target biopsy cores show higher Gleason grade; Group 2: target sector biopsy cores show equal or 
higher Gleason grade. Overall “final Gleason grade” listed as highest Gleason score per patient
Overall Group 1 Group 2 p value
Target cores positive 158/228 (69.3 %) 76/106 (71.7 %) 82/122 (67.2 %) 0.476
Background cores positive 344/1881 (18.38 %) 101/876 (11.5 %) 243/1005 (24.2 %) <0.001
Core mean length: range (median) 5.6–14.7 (10.35) 5.6–14.7 (10.15) 6.5–14.5 (10.5) 0.555
Final Gleason grade (n = 76) (n = 41) (n = 48) 0.122
3 + 3 9 (11.8 %) 8 (9 %) 3 (3.4 %)
3 + 4 32 (42.1 %) 21 (23.6 %) 19 (21.3 %)
4 + 3 14 (18.4 %) 4 (4.5 %) 12 (13.4 %)
8 5 (6.6 %) 3 (3.4 %) 3 (3.4 %)
9 15 (19.7 %) 5 (5.6 %) 10 (11.2 %)
10 1 (1.4 %) 0 (0 %) 1 (1.1 %)
Fig. 2  Box-and-whiskers plots comparing target volumes. The 
median target volume for Group 1 (0.54 cm3) was significantly lower 
than for Group 2 (1.65 cm3). The upper and lower limits of the boxes 
represent the 75th and 25th percentiles of the data, respectively, with 
the line in the box representing the median value; whiskers represent 
data within 1.5 times the interquartile range
 World J Urol
1 3
Gleason grade. Smaller targets were shown to upgrade 
tumors compared to background sampling, irrespective of 
whether absolute tumor size or tumor size relative to the 
gland was used. In routine practice, it is easier to define 
the two-dimensional measurements of a target rather than 
to determine volume, which requires multiple tumor out-
lines to be drawn and possibly the use of additional soft-
ware. It is therefore clinically relevant to note that the short 
axis measurement of targets demonstrated the highest sen-
sitivity and specificity, with a cutoff value of 1.0 cm. The 
improved performance of the short axis may reflect the fact 
that prostate tumors, and therefore targets, are often ellip-
tical rather than circular, particularly in the anterior gland 
[23]. This is analogous to assessment of lymphadenopathy, 
where short axis measurements are the most sensitive indi-
cator of tumor involvement [24]. Although further studies 
are required to validate this approach, this could provide a 
simple clinical metric for the determination of whether a 
lesion requires MRI targeting or not.
Target sector biopsy had a higher percentage of positive 
cores (69.3 %) compared to background cores (18.4 %). 
This was expected and is similar to previously published 
Table 4  Lesion size parameters as a predictor of the incremental benefit of targeted cores
Group 1: target biopsy cores show higher Gleason grade; Group 2: target sector biopsy cores show equal or higher Gleason grade. Longest axial 
diameter relates to the maximal axial diameter of targets, and shortest diameter is the measurement perpendicular to this
AUC area under the curve, TD transverse diameter, APD antero-posterior diameter
Group 1 Group 2 p value AUC Cutoff Spec (%) Sens (%)
Target volume (cm3) 0.54 (0.41–1.04) 1.65 (1.08–2.78) <0.001 0.837 0.815 85.4 68.3
Target volume as % of gland volume (%) 1.18 (0.83–1.93) 4.76 (1.90–7.09) <0.001 0.837 2.348 70.8 87.8
Target longest axial diameter (cm) 1.37 (1.09–1.90) 2.04 (1.64–2.48) <0.001 0.738 1.825 66.7 73.2
Target longest axial diameter as  % of prostate TD (%) 27.8 (20.5–36.0) 42.3 (32.2–52.7) <0.001 0.798 32.0 75.0 68.3
Target longest diameter as  % of APD (%) 34.3 (27.8–47.7) 57.9 (40.9–70.2) <0.001 0.784 53.3 58.3 87.8
Target shortest axial diameter (cm) 0.73 (0.65–0.98) 1.26 (1.08–1.71) <0.001 0.886 0.995 83.3 82.9
Target shortest axial diameter as % of TD (%) 14.6 (12.0–17.1) 26.3 (22.4–32.5) <0.001 0.927 19.1 89.6 85.4
Target shortest diameter as % of prostate APD (%) 18.5 (15.9–24.2) 36.9 (28.0–43.9) <0.001 0.888 29.6 72.9 92.7
Fig. 3  Comparing shortest axial diameter. The highest AUC for dif-
ferentiating the two groups was demonstrated for the shortest axis 
diameter of the targets. a Box-and-whiskers plots and b receiver oper-
ating characteristics curves showing a significantly smaller measure-
ment in Group 1, with a cutoff of 1.0 cm achieving a sensitivity of 
83.3 and a specificity of 82.9 and a area under the curve (AUC) of 
0.886
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rates for positive target cores (range 46–67 %) and positive 
background cores (range 7.5–22 %) [13, 25, 26]. Group 2 
had significantly more background cores positive (24.2 %) 
than Group 1 (11.5 %), which likely reflects the larger 
targets which involved more of the gland. Interestingly, 
there was no correlation between larger target size and an 
increased number of target cores obtained, which suggests 
that the clinicians performing the biopsy were attempting 
to limit the overall biopsy cores taken. There was a positive 
correlation between percentage core involvement by cancer 
and tumor volume, which serves as a quality control evalu-
ation for correct needle placement.
Our study has some limitations, including its retrospec-
tive nature. The cohort studied was predominantly a re-
biopsy population (63/76 patients that had at least one prior 
biopsy). This may have introduced a selection bias toward 
smaller and more anterior tumors that would be missed by a 
TRUS approach. However, such a cohort represents the more 
typical patient population undergoing TP biopsy in current 
clinical practice. Location of a target was not assessed, and 
this may also be an important consideration in the utility of 
a targeted biopsy: For instance, if the target is remote from 
the location of the standard sectoral biopsy core, it is more 
likely to add value over the non-targeted biopsy (Fig. 4). 
However, this is difficult to objectively define, and target size 
will be an inherent confounding factor. Target cores were 
obtained before the background biopsies in this study. The 
initial biopsy could potentially reduce the volume of very 
small tumors or may affect the detection rate in subsequent 
cores, due to biopsy-induced hemorrhage. However, this 
effect would be similar between the two groups and there-
fore should not affect the outcome of this study.
Image-guided biopsy has been shown to improve can-
cer detection in patients with a previous negative prostate 
biopsy [27], as well as to reduce the detection rate of insig-
nificant cancers [13]. As a result, targeted biopsy has the 
potential to reduce the number of cores required to diag-
nose significant prostate cancer, and theoretically, this 
could be used in isolation, without the need for a back-
ground biopsy [26, 28, 29]. While recent improvements 
in MRI have made it a sensitive technique for identifying 
tumor, the diagnostic challenge is to accurately character-
ize the index lesion while at the same time providing suf-
ficient reassurance that there is no tumor when the MRI is 
negative, that is maximizing both sensitivity and negative 
predictive value (NPV). However, several published papers 
have shown that while MRI is sensitive, it does not yet have 
a sufficiently high NPV to provide the reassurance that 
there is no tumor elsewhere in the gland and therefore can-
not currently be used to exclude the need for a biopsy of 
these areas. Consequently, the standard for prostate cancer 
detection remains a combination of targeted and systematic 
background biopsy cores [13, 17]. Although the current 
study does not directly define the added morbidity of addi-
tional cores acquired from larger-volume targets, previous 
work has shown that an increasing number of biopsy cores 
are associated with an elevated risk of morbidity, as well 
as complications at subsequent prostatectomy [18, 19]. 
Therefore, it is likely that the targeted biopsies acquired 
from these larger lesions provide little additional diagnostic 
information, but an increased risk of morbidity. Future pro-
spective trials are required to evaluate this further.
In conclusion, the results of the study suggest that if a 
combined systematic and targeted transperineal prostate 
biopsy is performed, there is limited benefit in acquiring 
additional cores from larger-volume targets, when the short 
axis diameter is >1.0 cm.
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